Ironwood Pharmaceuticals, Inc.
A Boston-based biotechnology company that develops and sells medicines for digestive and rare diseases, best known for Linzess, a prescription treatment for chronic constipation and irritable bowel syndrome. It began in 1998 as Microbia, founded by postdocs from a Whitehead Institute lab, and renamed itself Ironwood in 2008 after the long-lived desert tree that shelters other plants — a nod to endurance. Its flagship drug linaclotide was discovered by those same early researchers.
Granted 121.6K · Bought 1.35M · Sold 6.73M
Sold 1.60M
Granted 202.3K · Bought 1.00M
Bought 2.1K · Sold 3.55M
Sold 19.0K
Granted 1.87M · Bought 50.0K · Sold 725.8K
Granted 3.53M · Sold 1.58M
Granted 778.5K · Sold 206.7K
Granted 460.1K · Sold 103.6K
Granted 49.2K
Granted 12.3K
Granted 70.1K · Sold 42.1K
Granted 2.22M · Sold 1.76M
Granted 679.4K · Sold 178.9K
Granted 532.5K · Sold 61.9K
Granted 448.0K · Sold 55.4K
Granted 347.8K · Sold 212.8K
Granted 168.5K
Granted 136.6K · Sold 31.4K
Granted 541.0K · Sold 361.9K
Granted 346.7K · Bought 46.8K · Sold 17.6K
Granted 247.7K · Sold 35.3K
Granted 176.7K · Sold 54.4K
Granted 176.7K · Bought 25.0K
Granted 511.3K · Sold 261.4K
Granted 345.0K · Sold 94.3K
Granted 246.9K · Bought 6.9K
Granted 235.0K
Granted 246.9K · Sold 17.5K
Granted 255.0K
Granted 261.4K · Sold 80.0K
Granted 103.9K · Sold 2.1K
Granted 101.2K · Bought 22.0K · Sold 31.3K
Granted 50.0K · Sold 1.92M
Granted 22.8K · Sold 8.5K
Granted 29.7K
Granted 61.1K · Sold 41.3K
Granted 141.9K · Sold 50.5K
Granted 91.9K
Granted 1.8K
Granted 44.5K · Sold 2.4K
Granted 42.3K
Granted 112.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Denner Alexander JDirector · 12 transactions | — | 18.96M | 121.6K | 1.35M | 6.73M |
| FIL Ltd +1 co-filerReporting owner · 42 transactions | — | 17.07Mas of Mar 2013 | — | — | 1.60M |
| Denner Alexander J +1 co-filerDirector, 10% owner, 10% owner · 29 transactions | — | 16.17M | 202.3K | 1.00M | — |
| Ridgeback Capital Investments L.P. +2 co-filers10% owner · 67 transactions | — | 6.84Mas of Feb 2012 | — | 2.1K | 3.55M |
| FMR LLCReporting owner · 2 transactions | — | 2.34Mas of Jul 2012 | — | — | 19.0K |
| Hecht Peter MChief Executive Officer, Director · 69 transactions | — | 2.23Mas of Mar 2019 | 1.87M | 50.0K | 725.8K |
| MCCOURT Thomas AChief Executive Officer, Director · 82 transactions | — | 1.90M | 3.53M | — | 1.58M |
| Hove Anders D +7 co-filers10% owner · 5 transactions | — | 1.52Mas of Mar 2013 | — | — | — |
| Shetzline MichaelSVP, CMO, Head-Res&Drug · 34 transactions | — | 1.18M | 778.5K | — | 206.7K |
| Silver RonaldPFO & PAO · 29 transactions | — | 858.1K | 460.1K | — | 103.6K |
| Conrades George HDirector · 37 transactions | — | 771.6Kas of Jun 2015 | 49.2K | — | — |
| Shaw David EvansDirector · 23 transactions | — | 722.6Kas of Mar 2014 | 12.3K | — | — |
| Cook Joseph C JrDirector · 35 transactions | — | 701.0Kas of Mar 2015 | 70.1K | — | 42.1K |
| Currie Mark GDirector · 102 transactions | — | 676.9K | 2.22M | — | 1.76M |
| John MinardoChief Legal Officer · 20 transactions | — | 500.5K | 679.4K | — | 178.9K |
| Mallon MarkChief Executive Officer, Director · 9 transactions | — | 493.2Kas of Feb 2021 | 532.5K | — | 61.9K |
| Consylman GinaSVP, CFO & Treasurer · 48 transactions | — | 392.6Kas of Mar 2021 | 448.0K | — | 55.4K |
| Rickard JasonSVP, Chief Operating Officer · 35 transactions | — | 376.3Kas of Mar 2023 | 347.8K | — | 212.8K |
| Walsh Christopher T PHDDirector · 27 transactions | — | 374.5Kas of Mar 2017 | 168.5K | — | — |
| Gaskins Tammi LChief Commercial Officer · 6 transactions | — | 350.4K | 136.6K | — | 31.4K |
| Higgins Michael JChief Operating Officer · 17 transactions | — | 329.1Kas of Dec 2014 | 541.0K | — | 361.9K |
| Emany Sravan KumarSVP, COO and CFO · 12 transactions | — | 309.6Kas of Nov 2024 | 346.7K | 46.8K | 17.6K |
| Martini Gregory S.Chief Financial Officer · 6 transactions | — | 297.2K | 247.7K | — | 35.3K |
| Davis AndrewSVP, Chief Business Officer · 11 transactions | — | 284.7Kas of Nov 2024 | 176.7K | — | 54.4K |
| Owens Edward PDirector · 16 transactions | — | 281.7Kas of Jun 2021 | 176.7K | 25.0K | — |
| Gilbert Halley EChief Admin Officer & SVP · 45 transactions | — | 278.6Kas of Feb 2020 | 511.3K | — | 261.4K |
| McHugh JulieDirector · 28 transactions | — | 272.3K | 345.0K | — | 94.3K |
| Duane Jon RDirector · 10 transactions | — | 253.8K | 246.9K | 6.9K | — |
| Shepard JayDirector · 8 transactions | — | 235.0K | 235.0K | — | — |
| Kessler Marla LDirector · 11 transactions | — | 229.4K | 246.9K | — | 17.5K |
| Dreyfus AndrewDirector · 22 transactions | — | 228.3Kas of Jun 2025 | 255.0K | — | — |
| Moukheibir CatherineDirector · 20 transactions | — | 181.4K | 261.4K | — | 80.0K |
| McGuire TerranceDirector · 53 transactions | — | 144.4Kas of Apr 2019 | 103.9K | — | 2.1K |
| Fanucci MarshaDirector · 11 transactions | — | 132.7Kas of Apr 2019 | 101.2K | 22.0K | 31.3K |
| Roberts Bryan EDirector · 81 transactions | — | 124.0Kas of Jun 2015 | 50.0K | — | 1.92M |
| Kilroy ConorSVP, GC & Secretary · 9 transactions | — | 122.3Kas of Feb 2021 | 22.8K | — | 8.5K |
| Ebersman David ADirector · 6 transactions | — | 101.2Kas of Mar 2015 | 29.7K | — | — |
| MacDonald KellyChief Accounting Officer · 22 transactions | — | 98.7Kas of Dec 2020 | 61.1K | — | 41.3K |
| Olanoff Lawrence SDirector · 26 transactions | — | 91.4Kas of Jun 2021 | 141.9K | — | 50.5K |
| Williams Douglas EDirector · 6 transactions | — | 87.8Kas of Apr 2019 | 91.9K | — | — |
| Venrock Associates +3 co-filers10% owner · 2 transactions | — | 50.8Kas of Mar 2013 | — | — | — |
| VR Management LLC10% owner · 22 transactions | — | 42.7Kas of Mar 2013 | 1.8K | — | — |
| Graney ThomasChief Financial Officer · 6 transactions | — | 42.0Kas of Feb 2017 | 44.5K | — | 2.4K |
| Schulman Amy WDirector · 8 transactions | — | 38.2Kas of Apr 2019 | 42.3K | — | — |
| Huyett WilliamChief Operating Officer · 5 transactions | — | 27.5Kas of Apr 2019 | 112.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -17.33M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.